

	Compound Name/Code	Phase II	Phase III	Submission	Approval
Neurology	Aricept (Jelly Formulation) JP	*	*	*	*
	Aricept (Vascular Dementia) US	*	*	*	
	Aricept (Sustained Release Formulation) US	*	*	*	
	Aricept (Lewy Body Dementia) JP	*			
	E2007 (Epilepsy) US, EU, JP	*1)	*1)		
	E2007 (Neuropathic Pain) US, EU	*			
	E2007 (Multiple Sclerosis) EU	*			
	E2007 (Migraine Prophylaxis) US	*			
	Inovelon/Banze/E2080 (Lennox-Gastaut syndrome) South Korea,JP	*	*2)	*	*2)
	AS-3201 (Diabetic Neuropathy) US, EU		*		
	Zonegran (Orally Disintegrating Tablet) EU	*	*	*	
	Zonegran (Pediatric Indication) EU	*	*		
	Zonegran (Epilepsy, Monotherapy) EU	*	*		
	E0302 (Amyotrophic Lateral Sclerosis(ALS)) JP		*		
	E2014 (Cervical Dystonia) JP	*	*	*	
SEP-190 (Insomnia) JP	*	*			
Oncology & Supportive Care	E7389 (Breast Cancer) US, EU, JP	*	*	*3)	
	E7389 (Non-Small Cell Lung Cancer) US	*			
	E7389 (Prostate Cancer) US, EU	*			
	E7389 (Sarcoma) EU	*			
	E7820 (Colorectal Cancer) US	*			
	E7080 (Thyroid Cancer) US, EU	*			
	E7080 (Endometrial Cancer) US	*			
	MORAb-003 (Ovarian Cancer) US,EU	*	*		
	MORAb-009 (Mesothelioma) US, EU	*			
	Dacogen (Five-Day Dosing Regimen for MDS) US	*	*	*	*
	Dacogen (Acute Myelogenous Leukemia(AML)) US	*	*		
	irofulven (Prostate Cancer) US	*			
	AKR-501 (Idiopathic Thrombocytopenic Purpura) US	*			
	AKR-501 (Thrombocytopenia associated with liver disease) US	*			
	amolimogene (Cervical Dysplasia) US		*		
Saforis (Oral Mucositis) US	*	*			
Vascular & Immunological Reaction	Humira (Psoriasis) JP	*	*	*	*
	Humira (Crohn's Disease) JP		*	*	
	Humira (Ankylosing Spondylitis) JP	*	*	*	
	Humira (Juvenile Rheumatoid Arthritis) JP	*	*		
	Humira (Inhibition of Structural Damage of Joints) JP	*	*		
	Humira (Ulcerative Colitis) JP		*		
	E5564 (Severe Sepsis) US, EU, JP	*	*		
	E5555 (Acute Coronary Syndrome) US, EU, JP	*			
	E5555 (Atherothrombotic Disease) US, EU, JP	*			
	E6201 (Psoriasis) US,EU	*			
	T-614 (Rheumatoid Arthritis) JP	*	*		
Tambocor (Tachyarrhythmia in Paediatric Patients) JP	*	*	*	*	
Gastro-intestinal Disorders	Pariet (Helicobacter pylori Eradication by Concomitant Therapy) JP	*	*	*	
	Pariet (Non-erosive GERD) JP	*	*	*	
	Pariet/Aciphex (Long-Acting Release Formulation) US,EU	*	*	*	
	Pariet (Additional Dosage for Reflux Esophagitis) JP		*	*	
	Pariet (Functional-dyspepsia) JP	*			
	Gasmotin (Gastroprokinetic Agent) Asia	*	*	*4)	*4)
Other Therapeutic Areas	KES524 (Obesity Management) JP	*	*	*	
	clevidine (Chronic Hepatitis B) Asia	*	*5)	*5)	
	Glufast (Diabetes) Asia	*	*	*6)	*6)
	Urief (Dysuria Associated with Benign Prostatic Hyperplasia) Asia	*	*	*7)	

Updated: May 14, 2010

- 1) Phase IIIs for epilepsy indication are ongoing in US and EU. A Phase II is ongoing in Japan.
- 2) Approval was obtained in Korea. A Phase III is ongoing in Japan.
- 3) Applications are under review in Switzerland, Singapore, US, EU and Japan.
- 4) Approval was obtained in Philippines. Applications are under review in Malaysia, Indonesia, and Vietnam. Submission is in preparation in four other Asian countries including some ASEAN members.
- 5) Applications are under review in Malaysia, Thailand, Indonesia, and India. Submission is in preparation in two ASEAN countries. A Phase III study is being prepared in China.
- 6) Approval was obtained in Philippines and Thailand. Applications are under review in Malaysia, Indonesia, and Singapore. Submission is in preparation in five ASEAN countries.
- 7) Application is under review in Singapore. Submission is in preparation in nine ASEAN countries.